Teva Pharmaceutical's Potential Catalysts and Market Momentum
Teva Pharmaceutical Industries Limited (TEVA) is experiencing a significant stock surge, driven by potential FDA approval of its long-acting schizophrenia drug olanzapine, momentum in its specialty drugs, and an anticipated biosimilar boom. Analysts are optimistic about the stock reaching $40 or more, with 12 out of 15 analysts rating it as a 'buy' or 'strong buy'.
Tickers: $TEVA
Topics: FDA approval market catalyst pharmaceuticals schizophrenia drug Teva